-
Taijul puts Bangladesh on brink of Test series win over Pakistan
-
Iran warns against renewed US attacks as Trump says held off assault
-
France says G7 finance talks 'frank, sometimes difficult'
-
England sweat on skipper Sciver-Brunt's fitness before T20 Women's World Cup
-
Ronaldo, 41, leads Portugal into his sixth World Cup
-
Stocks rise, oil dips after Trump holds off on Iran attack
-
Pakistan court sentences man to death for killing teen influencer
-
Nicaragua's exiled Sergio Ramirez: Autocrats 'don't care' about novels
-
Robertson and McGinn in Scotland squad bidding for World Cup breakthrough
-
Spanish ex-PM Zapatero under investigation for influence peddling
-
Pep Guardiola: Catalan genius who changed football
-
Long-running conflicts muddy DR Congo Ebola response
-
Bayeux Tapestry to be shown flat for first time in London exhibit
-
Albania appoint coach Rolando Maran as Sylvinho's successor
-
Germany starts sale of bailed-out energy firm Uniper
-
Iran civilians learn assault rifle basics to fend off US
-
Beijing says China, US should work together to promote AI governance
-
Mango founder's son arrested in Spain over father's death
-
Neuer set for return to Germany World Cup squad: reports
-
US police investigating deadly mosque shooting as hate crime
-
WHO worried about 'scale and speed' of deadly Ebola outbreak
-
Seabird habitats shrink as ocean heats up: study
-
Government encourages women to report rape in French star's assault probes
-
Germany starts sales process for bailed-out energy firm Uniper
-
Europe-China spacecraft launches to study Earth's 'invisible armour'
-
Tech stocks retreat, oil dips after Trump holds off on Iran attack
-
Stellantis joins race to build mini-EVs for Europe
-
How might this World Cup be won on the pitch?
-
Malians tell of torture and killings by army, Russian fighters
-
EU-China spacecraft takes off on mission to probe solar winds
-
Under Trump pressure, EU eyes deal to end trade standoff
-
'We're here solely to play football,' insists North Korean coach
-
Putin trip aims to show China ties unshakeable after Trump pomp
-
Hanoi hits the brakes on petrol bike ban
-
Japan economy grows faster than expected in first quarter
-
World Cup glory attracts superstar coaches into international battle
-
Stuttering Sabalenka seeks to set down marker at Roland Garros
-
'Little' Freiburg chasing glory in debut European final
-
Villa inspired by former heroes as they target Europa League glory
-
Irrepressible Sinner primed for career Grand Slam at Roland Garros
-
China market for Nvidia AI chips to open 'over time': Huang
-
Asian markets cautious, oil dips after Trump holds off on Iran attack
-
Three killed in San Diego mosque shooting, both suspects dead
-
Love, lust and gnomes as top UK flower show bursts into bloom
-
Fans of historic DC park wary of Trump plan to 'beautify' city
-
As bee population collapses, US apiarists fear research cuts
-
Lights out for Cuban students as blockade bites
-
Campaigners warn Italy's gutted rape bill could help assailants
-
Libyan ex-prison boss faces ICC war crimes hearing
-
Argentine scientists lay first traps in hantavirus hunt
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
W.AbuLaban--SF-PST